BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4510 related articles for article (PubMed ID: 3316511)

  • 21. Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells.
    Herlyn D; Powe J; Ross AH; Herlyn M; Koprowski H
    J Immunol; 1985 Feb; 134(2):1300-4. PubMed ID: 3965572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased responsiveness to macrophage-activating factor (MAF) after alteration of macrophage membranes.
    Piessens WF; Remold HG; David JR
    J Immunol; 1977 Jun; 118(6):2078-82. PubMed ID: 325137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influences of inflammatory macrophages on the proliferation of mouse tumor cells in vitro].
    Sun DM; Hu XZ; Shi W; Zhang YH
    Zhonghua Zhong Liu Za Zhi; 1986 Jul; 8(4):247-9. PubMed ID: 3093180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Requirements of adherent cells for activating Lyt-1+2- T cells as well as for functioning as antitumor effectors activated by factor(s) from Lyt-1+2- T cells.
    Sakamoto K; Fujiwara H; Nakajima H; Yoshioka T; Takai Y; Hamaoka T
    Jpn J Cancer Res; 1986 Nov; 77(11):1142-52. PubMed ID: 3098724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma.
    Ratliff TL; Thomasson DL; McCool RE; Catalona WJ
    J Reticuloendothel Soc; 1982 May; 31(5):393-7. PubMed ID: 6181257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon.
    Schreiber RD; Pace JL; Russell SW; Altman A; Katz DH
    J Immunol; 1983 Aug; 131(2):826-32. PubMed ID: 6408190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activation of mouse macrophages by rat lymphocyte mediators.
    Fidler IJ; Darnell JH; Budmen MB
    J Immunol; 1976 Aug; 117(2):666-73. PubMed ID: 950467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens.
    James SL; Lazdins JK; Hieny S; Natovitz P
    J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein.
    Barna BP; Deodhar SD; Gautam S; Yen-Lieberman B; Roberts D
    Cancer Res; 1984 Jan; 44(1):305-10. PubMed ID: 6690042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A.
    Fidler IJ; Darnell JH; Budmen MB
    Cancer Res; 1976 Oct; 36(10):3608-15. PubMed ID: 953987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor effect of adriamycin entrapped in liposomes conjugated with anti-human alpha-fetoprotein monoclonal antibody.
    Konno H; Suzuki H; Tadakuma T; Kumai K; Yasuda T; Kubota T; Ohta S; Nagaike K; Hosokawa S; Ishibiki K
    Cancer Res; 1987 Aug; 47(16):4471-7. PubMed ID: 2440568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrophage activation for microbicidal activity against Leishmania major: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes.
    Gilbreath MJ; Nacy CA; Hoover DL; Alving CR; Swartz GM; Meltzer MS
    J Immunol; 1985 May; 134(5):3420-5. PubMed ID: 3980997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production and utilization of human lymphokines containing macrophage-activating factor (MAF) activity.
    Kleinerman ES; Fidler IJ
    Lymphokine Res; 1983; 2(1):7-12. PubMed ID: 6381900
    [No Abstract]   [Full Text] [Related]  

  • 35. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.
    Murray HW; Spitalny GL; Nathan CF
    J Immunol; 1985 Mar; 134(3):1619-22. PubMed ID: 3918107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.
    Key ME; Talmadge JE; Fogler WE; Bucana C; Fidler IJ
    J Natl Cancer Inst; 1982 Nov; 69(5):1198-98. PubMed ID: 6957661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human macrophage-activating factors for cytotoxicity. I. Establishment of a human T-cell hybridoma that produces macrophage-activating factors for cytotoxicity.
    Higuchi M; Sugimoto M; Kobayashi Y; Osawa T
    Microbiol Immunol; 1987; 31(5):469-79. PubMed ID: 3116371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of adriamycin entrapped in liposomes conjugated with monoclonal antibody against tumor-associated antigen of bovine leukemia cells.
    Onuma M; Odawara T; Watarai S; Aida Y; Ochiai K; Syuto B; Matsumoto K; Yasuda T; Fujimoto Y; Izawa H
    Jpn J Cancer Res; 1986 Nov; 77(11):1161-7. PubMed ID: 3025145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of C3 as a marker of lymphokine-mediated macrophage activation.
    Koestler TP; Kirsh R; Kline T; Rieman D; Greig R; Poste G
    Cell Immunol; 1984 Aug; 87(1):1-14. PubMed ID: 6378389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles.
    Matthay KK; Heath TD; Papahadjopoulos D
    Cancer Res; 1984 May; 44(5):1880-6. PubMed ID: 6713389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 226.